Vyome (HIND) Q2 2026 earnings summary

Executive summary

• Completed merger with ReShape Lifesciences in August 2025, resulting in a Nasdaq listing and rebranding as a clinical-stage specialty pharmaceutical company focused on immune-inflammatory and rare diseases.

• Advanced lead VT-1953 program with positive Phase 2 data showing significant improvements in malodor, patient-reported outcomes, and lesion pain, with no treatment-emergent adverse events.

• Submitted pre-IND package to FDA and received feedback, with plans for further engagement to advance pivotal clinical studies.

• Expanded pipeline through an agreement with Impetis to in-license two selective JAK inhibitor assets targeting autoimmune and inflammatory diseases.

• Strengthened intellectual property with a granted Chinese patent for VB-1953 topical gel for inflammatory acne.

Financial highlights

• Revenue for the six months ended June 30, 2026 was $58,546, down from $248,535 year-over-year, reflecting the wind-down of legacy pharmaceutical operations.

• Net loss for the six months ended June 30, 2026 was $1,705,204, compared to $602,732 in the prior year period, driven by increased R&D and public company costs.

• Cash and cash equivalents increased to $7,887,510 as of June 30, 2026, up from $4,982,333 at December 31, 2025, due to ATM equity sales.

• Total current assets reached $8,200,000 as of June 30, 2026.

• Operating expenses rose to $2,020,809 for the six months ended June 30, 2026, from $701,839 year-over-year, mainly due to higher R&D and G&A expenses.

Outlook and guidance

• Management expects continued operating losses and increased expenses as clinical programs advance, with current cash expected to fund operations for at least 15 months, including initiation of pivotal VT-1953 trial.

• Plans to continue advancing VT-1953 clinical development in alignment with FDA feedback and further regulatory engagement.

• Intends to progress new JAK inhibitor assets using non-dilutive funding methods while maintaining focus on VT-1953.

• Additional funding will be required to complete clinical trials and support broader pipeline development.

• Maintains a disciplined capital structure with no debt, preferred stock, or toxic financing instruments.